Ex-Kite Execs Resurface with $300M and Control of Pfizer CAR-T Cells – Xconomy
CNBC |
Ex-Kite Execs Resurface with $300M and Control of Pfizer CAR–T Cells
Xconomy Arie Belldegrun and David Chang steered Kite Pharma last year to a historic FDA approval and a $12 billion bear hug from Gilead Sciences. Now they've re-emerged with a new startup, Allogene, which has $300 million in backing and the rights to a CAR–T … Pfizer signs a deal with Allogene to develop a cancer cell therapy Pfizer in deal with Allogene to develop cancer cell therapies – Reuters Pfizer inks deal handing CAR–T assets to newly launched biotech |
